Back from the brink: EGFR inhibition in gastroesophageal cancer

Mark R. Openshaw, David J. Pinato, Nicola Valeri

Research output: Contribution to journalArticlepeer-review

Abstract

Gastroesophageal adenocarcinomas (GEA) remain difficult to treat with limited targeted therapeutics. Negative results from randomized trials of EGFR inhibitors (EGFRi) in patients with molecularly unselected GEA have hampered the development of EGFRi in the gastroesophageal cancer space. A recent study reopens the game.

Original languageEnglish
Pages (from-to)2964-2966
Number of pages3
JournalClinical Cancer Research
Volume27
Issue number11
DOIs
Publication statusPublished - 1 Jun 2021

Fingerprint

Dive into the research topics of 'Back from the brink: EGFR inhibition in gastroesophageal cancer'. Together they form a unique fingerprint.

Cite this